Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Home / News / Pearce IP Blog

PEARCE IP BLOG

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Recent BioBlast® Updates

Biocon Reports 30% YOY Revenue Growth for Q2/24, Biosimilars Up 11%

Aug 8, 2024

On 8 August 2024, Biocon Limited reported year on year consolidated revenue growth of 30% for Q2 2024, primarily as a result of a “one-time gain” from the strategic collaboration between Biocon and Eris Lifesciences announced in March 2024.  Although revenue for...

Fresenius Withdraws Adalimumab Biosim from AU Market

Aug 7, 2024

Fresenius Kabi has walked away from the Australian adalimumab market and cancelled its approvals for 40mg Idacio® pre-filled syringe and 40mg Idacio® pen products which were approved as biosimilars to AbbVie’s Humira®.  The withdrawals are listed on the TGA Medicines...

Novo Nordisk Profits Soar in 2024 Mid-Year Report

Aug 7, 2024

On 7 August 2024, Novo Nordisk released its financial report which showed a strong increase in profits in the first half of 2024.  Novo Nordisk's total sales equalled DKK 133.4 billion in the first six months of 2024, an increase of 24% in DKK and 25% when measured...

Chugai In-Licenses Anti-TL1A Antibody RG6631 from Roche

Aug 7, 2024

Chugai announced that it has concluded a license agreement with Roche for Roche’s pipeline product RG6631, an anti-TL1A antibody, in late-stage product development for ulcerative colitis and Crohn’s disease.  Under the agreement, Chugai, which is 62% owned by Roche,...

Celltrion Denosumab Phase 3 Study Results

Aug 6, 2024

As reported in April this year, Celltrion presented the 78-week results of its Phase 3 study of CT-P41, biosimilar to Amgen’s Prolia® (denosumab), at the World Congress on Osteoporosis held in London from 11-14 April 2024.  On 6 August 2024, Celltrion announced that...

Lupin Completes Phase III Biosimilar Ranibizumab Trials

Aug 5, 2024

On 5 August 2024, Lupin announced the successful completion of a global Phase III clinical study of LUBT010, its biosimilar to Genentech’s Lucentis® (ranibizumab).  The study showed that LUBT010 has comparable efficacy, safety and immunogenicity to Lucentis® in...

Novo Nordisk Launches Wegovy® (Semaglutide) in Australia

Aug 2, 2024

On 2 August 2024, Australia’s Therapeutic Goods Administration announced that, according to Novo Nordisk, Wegovy® (semaglutide), specifically indicated for weight loss, will be available in Australia from early August 2024. While Wegovy® has been approved in Australia...

Certolizumab Biosimilar Rights Revert to Xbrane from Biogen

Aug 1, 2024

On 1 August 2024, Xbrane Biopharma announced that it will regain full rights to XcimzaneTM (BIIB801) biosimilar to UCB’s Cimzia® (certolizumab pegol) for rheumatoid arthritis and psoriasis.  Xbrane and Biogen had entered into a commercialisation and licensing...

New NSCLC Indication for BMS’ Opdivo® PBS-Listed

Aug 1, 2024

On 1 August 2024, Pharmacy Daily reported that Bristol Myers Squibb’s (BMS) Opdivo® (nivolumab) has had a new indication for resectable non-small cell lung cancer (NSCLC) listed on Australia’s Pharmaceutical Benefits Scheme (PBS).  It now joins MSD’s Keytruda®...

See Our BioBlast®

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here